Nagase Viita to Launch Injectable-grade Pharmaceutical Excipient "SUCROSE SG" in 2025

Sucrose is widely used as a stabilizer in biopharmaceuticals, a rapidly growing market. It helps maintain the quality of antibody drugs and lipid nanoparticles (LNPs) formulated with nucleic acid, such as COVID-19 vaccines.

Since its founding, sustainability and biotechnology have been at the core of Nagase Viita's business. SUCROSE SG is produced in an environmentally friendly way by using water instead of solvents.

Image2: https://cdn.kyodonewsprwire.jp/prwfile/release/M104815/202411119717/_prw_PI2fl_4w2ywc0c.jpg 

The name SOLBIOTE (TM) is derived from "Sol + Bio," representing biotechnology and the sun's gift of starch ("Sol" meaning "sun" in Latin). Nagase Viita's excipients are designed to provide innovative solutions for biopharmaceuticals, offering a stable supply and guaranteeing exceptional quality.

Find out more about SOLBIOTE (TM):
https://group.nagase.com/viita/en/highlights/solbiote/ 

View original content:https://www.prnewswire.co.uk/news-releases/nagase-viita-to-launch-injectable-grade-pharmaceutical-excipient-sucrose-sg-in-2025-302309451.html